General Information
Version
1.0
Revision date
2024-04-22
Product name
Mamyzin powder
Product Synonyms
Mamyzin® 269.5 mg/ml Powder; Ingel-Mamyzin® 269.4
1.2.1 Relevant identified uses
Veterinary product
1.2.2. Uses advised against
Safety Data Sheet only for the professional user., For veteri- on use nary use only, Refer to the product insert for complete instruc- tions on usage
Emergency telephone
+498007790900, +1 703-527-3887, +49800 1817059
Icons in SDS
Company Information
company name
Boehringer Ing. Pharma GmbH & Co. KG
e-mail address of the competent person responsible for the Safety Data Sheet
EHS-Services@Boehringer-Ingelheim.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H317, H334
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
Danger
Hazard statements
H317 May cause an allergic skin reaction. H334 May cause allergy or asthma symptoms or breath- ing difficulties if inhaled.
Prevention
P261 Avoid breathing dust. P280 Wear protective gloves. P284 Wear respiratory protection.
Response
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing. P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention. P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.
Hazardous Ingredients
Penethamate Hydroiodide
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumula- tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regu- lation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher. This drug is not subject to the labelling requirements under the Globally Harmonized System (GHS) The pharmacological effect of the medicament has to be considered (see package leaflet). May form combustible dust concentrations in air.
2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008) Respiratory sensitisation, Category 1 H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled. Skin sensitisation, Category 1 H317: May cause an allergic skin reaction.
